Inhibitors of phosphatidylinositol-3-kinase in cancer therapy
about
Mechanisms of drug resistance in kinases.Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.Multiple signal pathways in obesity-associated cancer.PIK3CA mutations predict recurrence in localized microsatellite stable colon cancerExpression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation.The role of phosphoinositide 3-kinase signaling in intestinal inflammationRecurrent oral cancer: current and emerging therapeutic approaches.Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapyDaunorubicin induces cell death via activation of apoptotic signalling pathway and inactivation of survival pathway in muscle-derived stem cells.Performance of in vitro γH2AX assay in HepG2 cells to predict in vivo genotoxicity.PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis.Glaucocalyxin A induces G2/M cell cycle arrest and apoptosis through the PI3K/Akt pathway in human bladder cancer cells.
P2860
Q27692567-04312717-BE8F-4137-80C7-7C017FC28824Q34153696-9F12A112-B8B5-44C8-9949-A9F5E6C90D63Q34633750-267A6775-9CD2-45B4-84B5-7642AA44A7CDQ35236785-C624B831-3555-4789-A004-CEE6C6019D32Q35845255-959981C8-5B6A-442E-8009-9300E0BE1835Q35915458-27368FF0-3700-4BFD-B1EC-D5E79BFFA46AQ36283038-CB9284A4-845F-41BD-AD2B-8E9DE27754F8Q37886009-19CB1B9A-0C0E-41A4-AF28-EDE599EDBD9BQ38242086-B4E155E9-3409-4FB6-856A-A958286C4D86Q38919020-DF996FF0-1B7A-45DC-931C-593EEF63FEBCQ39410853-4133E84F-C017-4446-9076-D30C2B46C1D9Q45816957-94600D2D-4625-4B54-837A-534CA306F2DCQ54568696-3227BFF1-81B9-4688-8869-5A2F8CFA9461Q55255581-CCC004E0-B617-4F0E-B1EE-4B2EF8477D6B
P2860
Inhibitors of phosphatidylinositol-3-kinase in cancer therapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibitors of phosphatidylinositol-3-kinase in cancer therapy
@en
Inhibitors of phosphatidylinositol-3-kinase in cancer therapy.
@nl
type
label
Inhibitors of phosphatidylinositol-3-kinase in cancer therapy
@en
Inhibitors of phosphatidylinositol-3-kinase in cancer therapy.
@nl
prefLabel
Inhibitors of phosphatidylinositol-3-kinase in cancer therapy
@en
Inhibitors of phosphatidylinositol-3-kinase in cancer therapy.
@nl
P2860
P1476
Inhibitors of phosphatidylinositol-3-kinase in cancer therapy
@en
P2093
Nathan T Ihle
P2860
P304
P356
10.1016/J.MAM.2010.02.003
P50
P577
2010-02-20T00:00:00Z